EXJADE
Total Payments
$2.3M
Transactions
230
Doctors
38
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $7,704 | 2 | 0 |
| 2023 | $18,303 | 4 | 1 |
| 2022 | $47,614 | 7 | 1 |
| 2021 | $51,764 | 9 | 1 |
| 2020 | $247,873 | 17 | 2 |
| 2019 | $249,217 | 28 | 2 |
| 2018 | $760,535 | 61 | 15 |
| 2017 | $963,108 | 102 | 29 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.3M | 201 | 99.5% |
| Consulting Fee | $8,268 | 4 | 0.4% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $1,825 | 2 | 0.1% |
| Travel and Lodging | $1,067 | 7 | 0.0% |
| Food and Beverage | $289.00 | 16 | 0.0% |
Payments by Type
Research
$2.3M
201 transactions
General
$11,449
29 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| OCULAR STUDY IN HEREDITARY HEMOCHROMATOSIS | Novartis Pharmaceuticals Corporation | $717,932 | 1 |
| A PHASE II STUDY OF DEFERASIROX IN LOW OR INTERMEDATE RISK MYELODYSPLASTIC SYNDROME IN PATIENTS WITHOUT CLINICALLY CONCERNING IRON OVERLOAD | Novartis Pharmaceuticals Corporation | $680,581 | 0 |
| A RANDOMIZED OPEN LABEL MULTICENTER TWO ARM PHASE II STUDY TO EVALUATE TREATMENT COMPLIANCE EFFICACY AND SAFETY OF AN IMPROVED DEFERASIROX FORMULATION GRANULES IN PEDIATRIC PATIENTS WITH IRON OVERLOAD | Novartis Pharmaceuticals Corporation | $484,836 | 0 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $144,356 | 18 |
| A MULTI CENTER RANDOMIZED DOUBLE BLIND PLACEBOCONTROLLED CLINICAL TRIAL OF DEFERASIROX IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES LOW INT1 RISK AND TRANSFUSIONAL IRON OVERLOAD TELESTO | Novartis Pharmaceuticals Corporation | $86,911 | 0 |
| PILOT STUDY TO ASSESS HEMATOLOGIC RESPONSE IN PATIENTS WITH UNFAVORABLE RISK AML AND OR MDS UNDERGOING MONOTHERAPY WITH EXJADE DEFERASIROX | Novartis Pharmaceuticals Corporation | $64,965 | 0 |
| AN OBSERVATIONAL MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DEFERASIROX IN THE TREATMENT OF PEDIATRIC PATIENTS WITH NON TRANSFUSION DEPENDENT IRON OVERLOAD | Novartis Pharmaceuticals Corporation | $35,589 | 0 |
| A RANDOMIZED OPEN LABEL MULTICENTER TWO ARM PHASE IISTUDY TO INVESTIGATE THE BENEFITS OF AN IMPROVEDDEFERASIROX FORMULATION FILM COATED TABLET | Novartis Pharmaceuticals Corporation | $27,473 | 0 |
| A MULTI CENTER RANDOMIZED DOUBLE BLIND PLACEBOCONTROLLED CLINICAL TRIAL OF DEFERASIROX IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES LOW INT1 RISK AND TRANSFUSIONAL IRON OVERLOAD TELESTO | NOVARTIS PHARMACEUTICALS CORPORATION | $24,837 | 3 |
| Ocular study in Hereditary Hemochromatosis | Novartis Pharmaceuticals Corporation | $14,315 | 1 |
| A randomized open label multicenter two arm phase II study to evaluate treatment compliance efficacy and safety of an improved deferasirox formulation granules in pediatric patients with iron overload | Novartis Pharmaceuticals Corporation | $11,692 | 0 |
| OCULAR STUDY IN HEREDITARY HEMOCHROMATOSIS | NOVARTIS PHARMACEUTICALS CORPORATION | $9,700 | 1 |
| REPRODUCTIVE CAPACITY AND ASSOCIATION TO IRON BURDEN AND CHELATION PATTERNS IN THALASSEMIA MAJOR PATIENTS | Novartis Pharmaceuticals Corporation | $9,000 | 0 |
| AN OPEN LABEL PHASE II RANDOMIZED PILOT STUDY TO ASSESS THE EFFECT IN TERM OF ERYTHROID IMPROVEMENT OF DEFERASIROX COMBINED WITH ERYTHROPOIETIN COMPARED TO ERYTHROPOIETIN ALONE IN PATIENTS WITH LOW AND INT1 RISK MYELODYSPLASTIC SYNDROME | Novartis Pharmaceuticals Corporation | $8,500 | 0 |
| A 5 YEAR PROSPECTIVE NON INTERVENTIONAL MULTICENTER REGISTRY IN SICKLE CELL DISEASE PATIENTS | Novartis Pharmaceuticals Corporation | $6,942 | 0 |
| OPEN LABEL PROSPECTIVE OBSERVATIONAL STUDY OF THE LONG TERM SAFETY OF EXJADE IN AN UNSELECTED POPULATION OF CHILDREN AGED 2 TO LESS THAN 6 YEARS AT STUDY ENTRY WITH TRANSFUSIONAL HEMOSIDEROSIS | Novartis Pharmaceuticals Corporation | $4,040 | 0 |
| ADHERENCE TO IRON CHELATION THERAPY AMONG PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE A RETROSPECTIVE STUDY | Novartis Pharmaceuticals Corporation | $3,000 | 0 |
Top Doctors Receiving Payments for EXJADE
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Oakland, CA | $2.1M | 140 |
| Amer Zeidan | Hematology & Oncology | New Haven, CT | $36,316 | 11 |
| , M.D | Ophthalmology | Burlington, MA | $21,600 | 6 |
| Samir Ballas | — | Philadelphia, PA | $15,545 | 7 |
| , MD | Hospitalist | Baltimore, MD | $15,545 | 7 |
| , MD | Pediatric Hematology-Oncology | Boston, MA | $14,190 | 4 |
| , MD | Hematology & Oncology | Buffalo, NY | $13,586 | 3 |
| Katharine Stansmore | — | Boston, MA | $12,022 | 2 |
| , MD | Internal Medicine | Durham, NC | $10,779 | 1 |
| , MD | Internal Medicine | Boston, MA | $10,500 | 2 |
| , M.D | Hematology | Duarte, CA | $7,186 | 1 |
| , M.D | Hematology | Cincinnati, OH | $7,186 | 1 |
| , MD | Pediatric Hematology-Oncology | Oakland, CA | $5,365 | 5 |
| , MD | Pediatrics | New York, NY | $4,252 | 4 |
| , M.D | Hematology & Oncology | Rochester, NY | $3,668 | 1 |
| , MD | Specialist | Little Rock, AR | $2,693 | 1 |
| , MD, PHD | Pediatric Hematology-Oncology | Nashville, TN | $2,693 | 1 |
| , M.D | Nephrology | Torrance, CA | $2,693 | 1 |
| , MD | Internal Medicine | Memphis, TN | $2,693 | 1 |
| , MD | Blood Banking & Transfusion Medicine | Saint Louis, MO | $1,992 | 4 |
| , M.D | Pediatric Hematology-Oncology | Oakland, CA | $1,714 | 1 |
| , MD | Pediatrics | New York, NY | $1,714 | 1 |
| , MD | Pediatric Hematology-Oncology | Chicago, IL | $1,714 | 1 |
| , M.D | Pediatrics | Philadelphia, PA | $1,714 | 1 |
| , MD | Hematology & Oncology | Augusta, GA | $1,637 | 5 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $2.3M
- Total Doctors 38
- Transactions 230
About EXJADE
EXJADE is a drug associated with $2.3M in payments to 38 healthcare providers, recorded across 230 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2024. In 2024, $7,704 was paid across 2 transactions to 0 doctors.
The most common payment nature for EXJADE is "Unspecified" ($2.3M, 99.5% of total).
EXJADE is associated with 17 research studies, including "OCULAR STUDY IN HEREDITARY HEMOCHROMATOSIS" ($717,932).